Luce-1

• Research type

  Research Study

• Full title

  A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects with Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa (LUCE-1)

• IRAS ID

  1009616

• Contact name

  Michael Murtagh

• Contact email

  mike.murtagh@aavantgardebio.com

• Sponsor organisation

  AAVantgarde Bio Corp. USA

• Eudract number

  2022-001092-14

• Research summary

  A study of an investigational therapy (AAVB-081) for the treatment of Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa. Multiple dose levels of the investigational therapy are planned to be assessed for its safety and potential for benefit.

• REC name

  North East - York Research Ethics Committee

• REC reference

  24/NE/0056

• Date of REC Opinion

  9 May 2024

• REC opinion

  Further Information Favourable Opinion